oversold stocks

Search documents
Top 2 Energy Stocks Which Could Rescue Your Portfolio This Quarter
Benzinga· 2025-06-24 11:34
Core Insights - The energy sector has several oversold stocks that present potential buying opportunities for undervalued companies [1] - The Relative Strength Index (RSI) is a key indicator for identifying oversold conditions, typically below 30 [1] Company Summaries - Clean Energy Technologies Inc (CETY) has an RSI of 29.9, with a recent stock price of $0.25, reflecting a 20% decline over the past month [7] - Black Stone Minerals LP (BSM) has an RSI of 28, with a recent stock price of $12.95, showing a 7% decline over the past five days [7]
3 Oversold Stocks Flashing Bullish Reversal Signals
MarketBeat· 2025-06-07 13:47
Group 1: Copart Inc. (NASDAQ: CPRT) - Copart's stock has experienced a significant decline, dropping over 21% from its all-time highs, with the Relative Strength Index (RSI) falling to 21, indicating it is deeply oversold and may be poised for a bounce [3][4]. - The recent plunge in Copart's stock price was attributed to an underwhelming earnings report, despite the company achieving its highest-ever revenue, which led to concerns that expectations had outpaced fundamentals [4][5]. - Analysts maintain a Neutral rating on Copart, with a price target of $55, suggesting that the stock is currently trading below its fair value, presenting an attractive risk/reward scenario [5]. Group 2: Cooper Companies Inc. (NASDAQ: COO) - Cooper Companies' stock has been on a downward trend, hitting multi-month lows with an RSI in the low 20s, indicating oversold conditions [7]. - Following a strong earnings report that exceeded expectations and reaffirmed full-year guidance of 10-15% EPS growth, the stock saw a nearly 6% increase in one day, with the RSI beginning to rise [8][9]. - Analysts have a 12-month price forecast of $100.38 for Cooper Companies, indicating a potential upside of 38.77% from the current price of $72.33 [6]. Group 3: UnitedHealth Group Inc. (NYSE: UNH) - UnitedHealth's stock has declined over 50% from its April highs due to disappointing earnings and negative market sentiment [10]. - Despite bearish trends, the stock has shown signs of stabilization, with the RSI remaining below 30 and a bullish crossover in the MACD, indicating potential for recovery [11]. - Analysts have reiterated positive ratings, with KeyCorp maintaining an Overweight rating and a price target of $400, suggesting a potential upside of over 35% from current levels [12].
Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER)
ZACKS· 2025-06-03 14:36
Group 1 - Omeros (OMER) has experienced a significant decline of 54.8% over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal [1] - The Relative Strength Index (RSI) for OMER is currently at 24.55, suggesting that the heavy selling pressure may be exhausting, which could lead to a price rebound [5] - There is strong consensus among Wall Street analysts that OMER will report better earnings than previously predicted, with a 6.9% increase in the consensus EPS estimate over the last 30 days [7] Group 2 - OMER holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8]
Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround
ZACKS· 2025-05-16 14:35
Core Viewpoint - Surrozen, Inc. (SRZN) has experienced significant selling pressure, resulting in a 29.7% decline over the past four weeks, but analysts anticipate better earnings than previously expected, indicating potential for recovery [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2] - SRZN's current RSI reading is 27.4, suggesting that the heavy selling may be exhausting, which could lead to a price rebound [5] Group 2: Fundamental Indicators - There has been a strong consensus among sell-side analysts to raise earnings estimates for SRZN, resulting in a 69.2% increase in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [6] - SRZN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [7]
Down -9.16% in 4 Weeks, Here's Why Exelon (EXC) Looks Ripe for a Turnaround
ZACKS· 2025-05-15 14:36
Core Viewpoint - Exelon (EXC) has experienced significant selling pressure, declining 9.2% over the past four weeks, but is now positioned for a potential trend reversal as it is in oversold territory, supported by analyst expectations of better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 indicating oversold conditions [2]. - EXC's current RSI reading is 28.78, suggesting that the heavy selling may be exhausting itself and a trend reversal could occur soon [5]. - The RSI helps investors identify potential entry opportunities when a stock is undervalued due to unwarranted selling pressure [3]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for EXC will improve, with a 1.3% increase in the consensus EPS estimate over the last 30 days [7]. - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [7]. - EXC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, indicating a strong potential for a turnaround [8].
Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ZACKS· 2025-05-15 14:36
Core Viewpoint - Allogene Therapeutics (ALLO) has experienced a significant decline of 31.9% over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Stock Performance and Technical Indicators - ALLO's stock has been under heavy selling pressure, leading to an RSI reading of 25.87, indicating it is oversold [5]. - The Relative Strength Index (RSI) is a momentum oscillator that helps identify oversold conditions when the reading falls below 30 [2]. - Stocks oscillate between overbought and oversold states, and an oversold condition may present entry opportunities for investors anticipating a rebound [3]. Group 2: Analyst Sentiment and Earnings Estimates - There is a strong consensus among sell-side analysts to raise earnings estimates for ALLO, resulting in a 0.4% increase in the consensus EPS estimate over the last 30 days [7]. - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [7]. - ALLO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, indicating a strong potential for a turnaround [8].
Down -57.05% in 4 Weeks, Here's Why You Should You Buy the Dip in AZUL (AZUL)
ZACKS· 2025-05-12 14:35
Core Viewpoint - AZUL has experienced significant selling pressure, declining 57.1% over the past four weeks, but is now positioned for a potential trend reversal as it is in oversold territory, supported by positive earnings forecasts from Wall Street analysts [1]. Group 1: Stock Performance - AZUL's stock has declined 57.1% in the last four weeks, indicating substantial selling pressure [1]. - The stock's Relative Strength Index (RSI) is currently at 23.35, suggesting it is oversold and may soon experience a trend reversal [5]. Group 2: Analyst Sentiment - There is strong consensus among sell-side analysts that AZUL will report better earnings than previously predicted, with the consensus EPS estimate increasing by 8.3% over the last 30 days [7]. - AZUL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8].
Here's Why HealthStream (HSTM) is Poised for a Turnaround After Losing -13.2% in 4 Weeks
ZACKS· 2025-05-07 14:35
Core Viewpoint - HealthStream (HSTM) has experienced a significant downtrend, with a 13.2% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to analysts' positive earnings outlook [1] Group 1: Stock Performance - HSTM's stock has faced heavy selling pressure, leading to a decline of 13.2% in the last month [1] - The stock's Relative Strength Index (RSI) is currently at 25.2, indicating it is oversold and may soon reverse its trend [5] Group 2: Analyst Sentiment - There is a strong consensus among sell-side analysts regarding HSTM's ability to exceed previous earnings estimates, with a 0.5% increase in the consensus EPS estimate over the last 30 days [7] - HSTM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a favorable outlook for a potential rebound [8]
Here's Why Phibro (PAHC) is Poised for a Turnaround After Losing -22.25% in 4 Weeks
ZACKS· 2025-04-16 14:35
Core Viewpoint - Phibro Animal Health (PAHC) has experienced significant selling pressure, resulting in a 22.3% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously expected, indicating potential for recovery [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) for PAHC is currently at 27.99, suggesting that the stock is oversold and may be nearing a price reversal due to exhausted selling pressure [5]. - RSI is a momentum oscillator that ranges from 0 to 100, with readings below 30 typically indicating that a stock is oversold [2][3]. Group 2: Fundamental Indicators - There is a consensus among sell-side analysts that earnings estimates for PAHC have increased by 0.1% over the last 30 days, which often correlates with price appreciation in the near term [7]. - PAHC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8].
Down -21.15% in 4 Weeks, Here's Why You Should You Buy the Dip in Criteo (CRTO)
ZACKS· 2025-04-15 14:35
Group 1 - Criteo S.A. (CRTO) has experienced a significant downtrend, with a stock decline of 21.2% over the past four weeks due to excessive selling pressure [1] - The stock is currently in oversold territory, indicated by an RSI reading of 29.99, suggesting that the heavy selling may be exhausting itself and a rebound could occur [5] - Wall Street analysts are optimistic about CRTO's earnings potential, with a consensus EPS estimate increase of 1.3% over the last 30 days, indicating a potential for price appreciation [7] Group 2 - CRTO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the likelihood of a near-term turnaround [8]